Freenome

As we look back on 2024, we extend our heartfelt gratitude to the people and partnerships that have made this year so impactful—including clinical study sites, patient advocacy groups, thought leaders, technology collaborators, and so many others. Your unwavering support and scientific contributions have been instrumental in advancing our mission to detect cancer in its earliest, most treatable stages. Collectively, we are making strides toward a future where early detection and accessible screening are the norm. We thank you for your continued partnership and commitment into 2025 and beyond, and we wish you a joyful holiday season and a happy new year!

We’re proud to join Fight Colorectal Cancer in support of the CRC Care Initiative. This groundbreaking effort is setting ambitious, actionable CRC goals to improve Colorectal Cancer screening and care. By leveraging real-world data and fostering collaboration across the industry, we’re committed to advancing health equity and addressing disparities in cancer care. Learn more about this important effort and how you can join us on this mission at https://FightCRC.org/CRCCI #ColorectalCancer #CRCCareInitiative #CancerAwareness

Earlier this week, Freenome attended the 2024 American College of Gastroenterology Annual Scientific Meeting in Philadelphia. Our participation highlighted key findings on blood-based colorectal cancer screening, cost-effectiveness, and diversity initiatives within our PREEMPT CRC study. We were honored that our poster, “Test Performance and Lesion Characteristics in Large Clinical Validation Study,” was recognized with the Presidential Poster Award. This recognition is given to less than 5% of accepted abstracts for high-quality, unique research. Congratulations to the authors on this recognition! We look forward to building on these insights and advancing efforts to close gaps in colorectal cancer care. #ACG2024 #EarlyCancerDetection #ColorectalCancer #Freenome #CRC Learn more about our research: https://lnkd.in/gWCzYHwt

Freenome is attending the American College of Gastroenterology Annual Scientific Meeting in Philadelphia from October 25-30. At Booth 574, we’ll share how our blood-based screening solutions are advancing the early detection of colorectal cancer when it’s most treatable. Our team will present key research, including insights into the projected benefits and cost-effectiveness of blood-based screening and how we’ve enhanced diversity in clinical trials to ensure better outcomes for everyone. Swipe to learn more about our presentations and how we’re working to close gaps in early cancer screening.

Last week, Riley Ennis, co-founder and Chief Product Officer at Freenome, joined Fight Colorectal Cancer and leading experts in colorectal cancer (CRC) prevention and care at a working session and dinner to unveil "The Colorectal Cancer Care Report: Improving Colorectal Cancer Prevention and Care in the United States." Freenome led the analysis for Goal 1 of the report - Timely Screening for the Prevention of CRC - to help develop standardized screening metrics that can be applied nationwide to improve screening rates and catch cancer early, when it’s most treatable. By collaborating with Fight CRC and leading experts, we can advance metrics that are grounded in solid research and widely accepted across institutions. It's a collective effort to build a standardized, data-driven approach to screening that can be scaled nationally, ultimately helping to close the care gap and save lives.

Today is World Lung Cancer Day, a time to raise awareness and support those affected by lung cancer, the leading cause of cancer deaths worldwide. At Freenome, we are developing blood tests to detect lung cancer early, when it is most treatable. The PROACT LUNG Study is intended to validate the clinical performance of a blood-based test for the early detection of lung cancer. We are currently enrolling as many as 20,000 individuals who meet specific criteria. Together, we can drive significant progress in early cancer detection. #WLCD24 #EarlyDetection #Freenome

Earlier this week, our CEO, Mike Nolan, shared his perspectives on how liquid biopsy innovations are reshaping cancer care at the 2024 Analytical, Life Science & Diagnostics Association (ALDA) Spring Senior Executive Conference in London:   “Blood-based technologies have vast potential to improve how we diagnose cancer, make treatment decisions, and monitor for disease resistance. Getting these tools into the clinic requires strong collaboration between life sciences and diagnostic companies. By working together with a shared purpose, we are determined to improve patient outcomes with innovations in liquid biopsy technologies - and set new standards of cancer care.”

We look forward to joining our colleagues and peers at Digestive Disease Week 2024 in Washington, D.C., May 18-21, where we will share our latest research in early cancer detection. If you are attending, stop by Booth 3351 to learn more about our work to outpace cancer.

Today, we want to take a moment to express our deepest gratitude to our incredible team members who are the driving force behind Freenome’s mission. As we continue to build our early cancer detection platform and advance the best portfolio of blood-based tests to meet the needs of patients, we are optimizing our structure and resources. We are confident in the role our blood-based tests will have in leveling the playing field for all people who need access to recommended cancer screenings. After thoughtful consideration, we have made the difficult decision to restructure our organization to better align with our strategic priorities. Unfortunately, this will eliminate some roles, impacting approximately 20% of our colleagues across multiple functions. We extend our appreciation to these individuals for being integral to our journey and for contributing to this remarkable team. We understand that these transitions bring challenges, and we are committed to supporting impacted team members through this process. If you are looking for talented and passionate individuals who have been instrumental in building a great culture, please reach out to hr@freenome.com. We appreciate your help in finding them their next opportunity.

Today, we announced topline results from our PREEMPT CRC Study, the largest clinical study to validate a blood-based test for the early detection of colorectal cancer. Read more in the press release here: https://lnkd.in/gr3PgG89